Trials / Withdrawn
WithdrawnNCT02578719
Greater Occipital Nerve (GON) Block Effectivity in the Treatment of Chronic Migraine: 6 Months Follow up
Placebo-Controlled Randomized Double Blind Trial of Blocking Greater Occipital Nerve Block With Bupivacaine Versus Saline in the Treatment of Chronic Migraine
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Bozok University · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates effectiveness of greater occipital nerve blocks with bupivacaine compared to placebo in chronic migraine patients.
Detailed description
The greater occipital nerve (GON), which derives most of its fibers from the C2 dorsal root, is the primary sensory nerve of the occipital region. The response to GON blockade was not simply dependent on the direct local anesthetic effect of the injection . The mechanism of action might have been via changes in brain nociceptive pathways. Another possible explanation for these findings is, therefore, that GON injections initiated diffuse noxious inhibitory controls, independent of anesthetic effect . Neurophysiological and clinical data suggest there is a functional connection between the sensory occipital segments and the trigeminal nociceptive system in humans.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bupivacaine | marcaine %0.5 20 ml flacon |
| DRUG | saline | %0.9 sodium chloride |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2018-07-01
- Completion
- 2018-07-01
- First posted
- 2015-10-19
- Last updated
- 2018-01-23
Source: ClinicalTrials.gov record NCT02578719. Inclusion in this directory is not an endorsement.